Get the Stockscreener App
17.74
1.44%
-0.26
After Hours:
17.75
0.01
+0.06%
Bausch Lomb Corp stock is traded at $17.74, with a volume of 285.72K.
It is down -1.44% in the last 24 hours and down -9.81% over the past month.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
See More
Previous Close:
$18.00
Open:
$18.01
24h Volume:
285.72K
Relative Volume:
0.55
Market Cap:
$6.25B
Revenue:
$4.68B
Net Income/Loss:
$-368.00M
P/E Ratio:
-16.90
EPS:
-1.05
Net Cash Flow:
$-58.00M
1W Performance:
-1.28%
1M Performance:
-9.81%
6M Performance:
+21.01%
1Y Performance:
+8.24%
1-Day Range:
$17.72
$18.10
1-Week Range:
$17.63
$18.55
52-Week Range:
$13.16
$21.69
Bausch Lomb Corp Stock (BLCO) Company Profile
Name
Bausch Lomb Corp
Sector
Industry
Phone
908-541-5456
Address
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
17.74 | 6.25B | 4.68B | -368.00M | -58.00M | -1.05 |
|
ISRG
Intuitive Surgical Inc
|
535.29 | 190.66B | 7.87B | 2.24B | 586.00M | 6.22 |
|
BDX
Becton Dickinson Co
|
228.46 | 66.26B | 20.18B | 1.71B | 3.07B | 5.94 |
|
ALC
Alcon Inc
|
84.06 | 41.58B | 9.76B | 1.16B | 665.00M | 2.34 |
|
RMD
Resmed Inc
|
231.67 | 34.01B | 4.81B | 1.11B | 1.35B | 7.55 |
|
WST
West Pharmaceutical Services Inc
|
335.56 | 24.30B | 2.88B | 499.60M | 321.60M | 6.74 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-15-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-10-24 | Initiated | Raymond James | Outperform |
| May-06-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-12-23 | Initiated | Stifel | Hold |
| Oct-03-23 | Resumed | Evercore ISI | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Mar-09-23 | Initiated | Needham | Hold |
| Dec-21-22 | Initiated | Barclays | Equal Weight |
| Sep-12-22 | Initiated | H.C. Wainwright | Buy |
| Jul-26-22 | Initiated | RBC Capital Mkts | Outperform |
| Jun-24-22 | Initiated | Evercore ISI | Outperform |
| Jun-06-22 | Initiated | Citigroup | Buy |
| May-31-22 | Initiated | Deutsche Bank | Hold |
| May-31-22 | Initiated | Goldman | Neutral |
| May-31-22 | Initiated | Guggenheim | Buy |
| May-31-22 | Initiated | JP Morgan | Neutral |
| May-31-22 | Initiated | Jefferies | Buy |
| May-31-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Initiated | Wells Fargo | Overweight |
| May-11-22 | Initiated | Cowen | Outperform |
View All
Bausch Lomb Corp Stock (BLCO) Latest News
Bausch + Lomb Corporation - Baystreet.ca
Bausch + Lomb to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
Ocular Prosthesis Market Trends, Challenges and Opportunities to 2030: A Projected $2.3 Billion Landscape - GlobeNewswire Inc.
Aesthetic Ophthalmology Devices Business Analysis Report 2024-2030 Featuring 40+ Key Players Including Abbott, Bausch & Lomb, Alcon, Allergan, Carl Zeiss, Haag Streit, Meditec, Topcon, Zeimer - Yahoo Finance
Bausch + Lomb down after report that Blackstone could back away from takeover bid - MSN
BofA rates Bausch & Lomb ‘underperform’ with lower buyout chances - MSN
Y Intercept Hong Kong Ltd Makes New Investment in Bausch + Lomb Co. (NYSE:BLCO) - MarketBeat
Short Interest in Bausch + Lomb Co. (NYSE:BLCO) Rises By 11.7% - MarketBeat
Janus Henderson Group PLC Purchases New Shares in Bausch + Lomb Co. (NYSE:BLCO) - MarketBeat
Bausch And Lomb Says Potential Sale In The Works - Law360
Bausch + Lomb exploring several options including a potential sale - Coast Reporter
Contact lens maker Bausch + Lomb says it is exploring sale - Reuters
Bausch + Lomb confirms it is exploring a potential sale - Financial Post
Bausch + Lomb responds to rumors of potential sale - Rochester Business Journal
Bausch + Lomb explores potential sale amid market rumors - Investing.com
Bausch + Lomb confirms board mulling sale of the company that would separate it from parent - MarketWatch
Bausch + Lomb explores sale amid separation plans - Investing.com
Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb - Jonesboro Sun
Bausch + Lomb Responds to Rumors of a Potential Sale - Business Wire
Eye health company Bausch + Lomb’s affiliate acquires Elios Vision - Yahoo Finance
Bausch & Lomb: Key Partner in Joint Takeover's Interest Reportedly Cools, Spooking Investors - Morningstar
King Street Capital Management L.P. Buys New Stake in Bausch + Lomb Co. (NYSE:BLCO) - MarketBeat
Bausch + Lomb acquires glaucoma surgery innovator - Investing.com
S&P 500 Futures Rise in Premarket Trading; Bausch + Lomb, Bio-Techne Lag - Barron's
Bausch + Lomb Acquires Elios Vision, Significantly Enhances Glaucoma Treatment Capabilities - Business Wire
Quadrature Capital Ltd Takes Position in Bausch + Lomb Co. (NYSE:BLCO) - MarketBeat
Bausch Lomb Corp Stock (BLCO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
0.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):